Table 76Quetiapine vs. FGA (Analysis of side effects)

Outcome or SubgroupkTotal NStatistical MethodEffect [95% CI]
6.1 Leaving the study early: 3: Adverse event (short-to-medium-term)5909RR (M-H, Fixed, 95% CI)0.37 [0.20, 0.67]
 6.1.1 vs HAL3682RR (M-H, Fixed, 95% CI)0.25 [0.11, 0.56]
 6.1.3 vs other FGA2227RR (M-H, Fixed, 95% CI)0.68 [0.26, 1.79]
6.2 AE: 1. Metabolic side effects - Weight gain (>=7% increase from baseline) (short-term)1209RR (M-H, Fixed, 95% CI)3.31 [0.80, 13.69]
 6.2.1 vs HAL1209RR (M-H, Fixed, 95% CI)3.31 [0.80, 13.69]
6.3 AE: 2. Neurologic side effects (treatment-emergent) - Any EPS (short-term)1RR (M-H, Fixed, 95% CI)Subtotals only
 6.3.1 vs HAL: EPS1209RR (M-H, Fixed, 95% CI)0.16 [0.08, 0.33]
6.4 AE: 2. Neurologic side effects (treatment-emergent) - Akathisia (short-term)1RR (M-H, Fixed, 95% CI)Subtotals only
 6.4.3 vs HAL: akathisia1209RR (M-H, Fixed, 95% CI)0.04 [0.01, 0.32]
6.5 AE: 2. Neurologic side effects - Use of anticholinergic medication (short-term)1288RR (M-H, Fixed, 95% CI)0.18 [0.05, 0.60]
 6.5.1 vs HAL1288RR (M-H, Fixed, 95% CI)0.18 [0.05, 0.60]

From: 10, Clinical evidence summary tables

Cover of Schizophrenia
Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update) [Internet].
NICE Clinical Guidelines, No. 82.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2009 Mar.
Copyright © 2009, National Collaborating Centre for Mental Health.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.